• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600993.SS
Share

Mayinglong Pharmaceutical Group Co., Ltd. Stocks

CN¥ 24.2Last Updated 15.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.48B

CN¥ 24.2
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Mayinglong Pharmaceutical Group Co., LTD. is a prominent Chinese entity primarily engaged in the manufacturing, wholesale, and retail of a diverse array of pharmaceutical products. Its extensive offerings encompass treatments for hemorrhoid, gynecological, cough, and skin conditions, alongside functional foods, traditional Chinese medicine drink tablets, and various medical devices. The company also facilitates sales through online channels. Expanding its operations, it additionally manages and runs its own hospitals. Headquartered in Wuhan, China, Mayinglong Pharmaceutical Group Co., LTD. possesses a rich history, having been founded in 1582.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, reasonably

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 08:30

Nuclear fusion projects have raised a record $4.5 billion. Is a new boom underway?

15.07.2026 07:30

Chinese AI developer DeepSeek has begun preparations for an IPO next year — Bloomberg

15.07.2026 03:24

Lucid's stock plummeted following news of a possible bankruptcy. At one point, it was down 57%.

15.07.2026 02:16

"The Prisoner's Dilemma": JPMorgan Warns of a Threat to Coinbase and Circle's Profits

15.07.2026 01:24

Inflation data pushed the indices higher. Software developers are under pressure again

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026